LSD Therapy

Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued

LSD Therapy Recent News

Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud
MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens
The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis the upcoming management elections this June 15.
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. 
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections
Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business highlights. Numbers show:
80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial
Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of the discov
LSD's Impact On The Body's Cannabinoid And Microorganisms Systems, New Study Sheds Light
A recent study published in the British Journal of Pharmacology looked into how psychedelics like LSD can affect the biological endocannabinoid system, otherwise targeted by cannabis compounds, which directly bind to cannabinoid receptors.
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon
MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.
LSD Microdosing Yields Positive Outcomes In Phase 1 Study, More Trials On Depression & Existential Distress
Holding company Blackhawk Growth Corp.(OTC: BLRZF)'s subsidiary company MindBio Therapeutics Pty Ltd shared the positive data gathered from its
Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings.
Using LSD To Treat Anxiety Is Showing Some Encouraging Findings In A Clinical Trial
A new scientific publication recently came out in the Biological Psychiatry journal announcing that results of an ongoing
Connecting To Nature Through Psychedelics